Elite Pharma Q2 FY2025 revenue $18.9M (+33% YoY); operating profit $3.5M (+84%)

ELITE PHARMACEUTICALS INC /NV/

2025-Q2 EPS reported -$0.01 revenue$37,683,408

Consolidated revenue $18.9M for Q2 ended Sep 30, 2024, up $4.7M or 33% vs prior year.
Operating profit $3.5M, up $1.6M or 84% YoY, driven by higher Elite label product sales.
Conference call scheduled for Nov 15, 2024 at 11:30 AM EST to discuss results and business update.
Stockholders can submit financial questions by 7 PM EST on Nov 14 via dianne@elitepharma.com.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.